Based on these results, Prothena has made the decision to discontinue the development of birtamimab. Topline results were announced from a phase 3 trial evaluating birtamimab in patients with ...

The decision to discontinue comes after the late-stage AFFIRM-AL clinical study evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint. The company’s shares have ...

"This is not the outcome that we expected, and we are surprised and disappointed by these results for patients, their families and caregivers, and for the entire AL amyloidosis community," said ...

These positive findings for NXC-201, which is a treatment for relapsed/refractory AL Amyloidosis, were presented at an oral presentation at the 2025 ASCO Annual Meeting in Chicago. The interim ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL amyloidosis missed its primary endpoint, prompting the biotech to end ...

Treatment modalities include liver transplantation for transthyretin-related (ATTR) amyloidosis, elimination of inflammation in amyloid A (AA) amyloidosis and intensive chemotherapy in ...

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track ...

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.

Figure 2: Interaction of RAGE with amyloid A fibrils, and RAGE-dependent activation of BV-2 transformed mononuclear phagocytes by SAA1.1. Figure 3: Effect of RAGE blockade on systemic amyloidosis ...

Demeritte had suffered from multiple myeloma, a cancer that forms in a type of white blood cell called plasma cells, and from amyloidosis, a rare disease that affected his heart. Upon receiving ...